Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Before the Bell: $5 Billion for WaMu; $39 Billion in Eye-Care


WaMu is shoring up its balance sheet with a $5 bln injection.

Morning Perspective: WaMu Gets $5 Billion

Bloomberg reports shares of Washington Mutual (WM) surged 17% in overseas trading this morning after the company said it may receive $5 billion from private equity firm TPG. This comes after the WaMu, the largest savings and loan in the U.S., lost 74% of its market value in the last 12 months. The company has been late to the game in the subprime market and has posted more than $3 billion in writedowns and loan losses. Last month, Standard & Poor's cut the company's credit rating to BBB from BBB+, two levels above junk status, and added that further reductions were possible. For more, Read Minyanville Editor Andrew Jeffery's column, WaMu Shores Up Balance Sheet .

From the Bull Pen: Bulls playing the upside bounce in the financials can use the financial ETF (XLF); sell-stops below $25.70.

From the Bear Cave: Bears are looking for a similar downside play in Wachovia (WB); entry near $30 with buy-stops set above the 50 DMA ($31.72).

$39 Billion in Eye-Care

According to Reuters, Novartis (NVS), Switzerland's second-largest drugs company, agreed to buy Nestlé's 77% stake in U.S. company Alcon (ACL). The deal, which could be worth up to $39 bln, would make Novartis the world's biggest maker of eye-care products. Novartis will first acquire a 25% stake for $11 billion at a 4% discount to ACL's Friday closing price, but the company will retain the option to acquire the remaining 52% for a fixed price of $28 billion between January 2010 and July 2011 marking a 22% premium. Among the reasons for the acquisition, Novartis CEO Daniel Vasella said "the margins are higher than our pharma business and are obviously very attractive." For context in the pharma space, read Todd's Quarterly Report Card: Grading the Tape.

From the Bull Pen: Another option for bulls is Wyeth (WYE). Sell-stops can be set below $39.

From the Bear Cave: Bears can play the downside in Pfizer (PFE); entry near $31.50 with near-term buy-stops above $22.

For more ideas, see Minyanville's Spotlight Stocks.

Quick Check Around the World

Asian trading closed with the Hang Seng +1.29%, Nikkei +1.18%, Sensex +2.70%, Taiwan +1.55% and Shanghai +4.45%.

Glancing towards Europe, we find the CAC +1.00%, DAX +0.98%, FTSE +0.93%.

As of 8:30 AM EST, S&P futures are higher +11 points to 1383, and Nasdaq futures are up +15 points to 1884.

A Look At Commodities

Commodities are mixed. Crude oil is higher +1.17 to 107.40. Gold is up +6.40 to 915.40. Silver is down -0.065 to 17.815, and copper is off -1.8 to 396.00.

The dollar index is higher +0.206 to 72.227.

On the Radar


3:00 Consumer Credit: $5.5 bln cons

Click here for the full trading radar.

Happy Monday! Have a great day!
No positions in stocks mentioned.

The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.

Featured Videos